[PDF] Top 20 CD28 costimulation improves expansion and persistence of chimeric antigen receptor–modified T cells in lymphoma patients
Has 10000 "CD28 costimulation improves expansion and persistence of chimeric antigen receptor–modified T cells in lymphoma patients" found on our website. Below are the top 20 most common "CD28 costimulation improves expansion and persistence of chimeric antigen receptor–modified T cells in lymphoma patients".
CD28 costimulation improves expansion and persistence of chimeric antigen receptor–modified T cells in lymphoma patients
... Targeted T cell immunotherapies using engineered T lymphocytes expressing tumor-directed chimeric anti- gen receptors (CARs) are designed to benefit patients with ...CAR-redirected T ... See full document
6
Elutriated lymphocytes for manufacturing chimeric antigen receptor T cells
... CAR T cells using autologous PBMC concentrates enriched for T cells by magnetic selection with the anti-CD3/CD28 ...stimulate T cell ...GD2-CAR T cells produced ... See full document
8
Car Drivers and Fuel Sources: How Distinct Signaling Domains in Chimeric Antigen Receptors Reprogram T Cells
... 100 patients with CD19+ hematological malignancies have been treated with the anti-CD19 CAR T ...CAR-modified T cells hold great promise as a treatment for a number of different ...the ... See full document
134
Incorporation of a hinge domain improves the expansion of chimeric antigen receptor T cells
... and lymphoma treatment, has a CD8α hinge [46, 47], while CD19RCD28 CAR uses a modified IgG4 hinge and Fc region [48], and also has a hinge-deleted version ...between CD28 and 41-BB costimulatory ... See full document
11
<p>Chimeric antigen receptor (CAR) T-cell therapy as a treatment option for patients with B-cell lymphomas: perspectives on the therapeutic potential of Axicabtagene ciloleucel</p>
... shortened persistence. Replacing the hinge and transmembrane domain from CD28 (as usual in Axi-cel) to eg, CD8-alpha lowers the cytokine levels in vitro and the side-effects in fi rst clinical ...model, ... See full document
12
Critical factors in chimeric antigen receptor-modified T-cell (CAR-T) therapy for solid tumors
... optimal T-cell subset as the material for preparing CAR-T can enhance the effect of the ...endogenous T cells, after receiving the pMHC signal, naive T cells differentiate into ... See full document
12
Chimeric antigen receptor-modified T cell therapy in chronic lymphocytic leukemia
... CAR-T cells in blood is positively associated with efficacy and toxicity in ...CAR-T cells approximately reach to 100/μl and 30/μl, respectively, the estimated probability of marrow ... See full document
12
Alloantigen specific regulatory T cells generated with a chimeric antigen receptor
... from CD28 and CD3ζ, both of which are necessary for Treg activation (47), suppressive capacity (48, 49), and homeostasis (50, ...from CD28 to lead to exhausted and less-potent Tconvs ...long-term ... See full document
13
CD19 CAR-T cell therapy for relapsed/refractory acute lymphoblastic leukemia: factors affecting toxicities and long-term efficacies
... the patients with R/R ALL can be induced into complete remission (CR), with a median overall survival (OS) of 4 months (range 2–6 months) ...in patients with CD19+, Philadelphia chromosome (Ph)––negative ... See full document
5
Highlights and summary of the 28th annual meeting of the Society for Immunotherapy of Cancer
... myeloid-derived cells responded poorly to therapy, result- ing in lower cytokine production and tumor necrosis after CpG-oligonucleotide treatment and deficient production of reactive oxygen species and ... See full document
14
Engineering CAR-T cells
... Chimeric antigen receptors (CARs) are engineered receptors that can graft an arbitrary specificity onto an immune effector cell (T ...extracellular antigen recognition domain of the ... See full document
6
Chimeric antigen receptor T cells: a novel therapy for solid tumors
... 14 patients with ad- vanced CEA+ malignancy ...CAR-T cells in Advanced Liver Malignancy (NCT02959151) and CAR-T Cells Targeting CEA Positive Cancer (NCT02349724) are ...CAR-T ... See full document
13
The potential of CAR T therapy for relapsed or refractory pediatric and young adult B-cell ALL
... CAR T-related encephalopathy syn- drome (CRES), can occur before, in association with, or after ...of patients who received a CTL019 infusion experienced some sort of neurologic event, the most common being ... See full document
12
Identification and selective expansion of functionally superior T cells expressing chimeric antigen receptors
... the T-cell manufactur- ing protocols utilized thus far by different clinical groups, rendering efforts to systematically optimize the produc- tion process a practical ...of T-cell properties and provide ... See full document
16
Advances of CD19-directed chimeric antigen receptor-modified T cells in refractory/relapsed acute lymphoblastic leukemia
... for patients administrated with lymphodepletion regimen prior to cell infusion, significantly higher than ...in patients without lymphodepletion (P < ...CAR-T cells in vivo and disease-free ... See full document
7
Chimeric antigen receptor-engineered T cells for cancer immunotherapy: progress and challenges
... CAR-modified T cells constitute a very appealing approach to cancer ...CAR-modified T cells, some severe adverse reactions were reported ...chemokine receptor for T ... See full document
7
T cells expressing chimeric antigen receptor promote immune tolerance
... target cells justifies use of stably transduced CAR T ...in antigen-specific peripheral tolerance, as MHC-matched second- ary skin grafts were accepted, while “third-party” grafts were ...Treg ... See full document
18
<p>Decitabine enhances cytotoxic effect of T cells with an anti-CD19 chimeric antigen receptor in treatment of lymphoma</p>
... tumor antigen, an extracellular spacer region (termed hinge), a transmembrane domain, CD3 ζ signaling domain, and usually costimulatory ...into T cells to express tumor antigen receptors, to ... See full document
12
Clinical trials of CAR-T cells in China
... targeted antigen. Therefore, B cell leukemia and lymphoma are the most common malignancies in CAR-T ...CAR- T therapy [45, 70, 73, ...cell lymphoma is under evaluation by FDA [25, ... See full document
10
From bench to bed: the tumor immune microenvironment and current immunotherapeutic strategies for hepatocellular carcinoma
... HCC cells not only has a positive association with PD-L1 ex- pression in HCC, moreover, it facilitates alternative acti- vation and chemotactic migration of TAMs via CSF1- CSF1R pathway in TAMs ...HCC cells ... See full document
21
Related subjects